GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Operating Margin %
中文

Sangui Biotech International (Sangui Biotech International) Operating Margin %

: -121.05% (As of Mar. 2023)
View and export this data going back to . Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Sangui Biotech International's Operating Income for the three months ended in Mar. 2023 was $-0.02 Mil. Sangui Biotech International's Revenue for the three months ended in Mar. 2023 was $0.02 Mil. Therefore, Sangui Biotech International's Operating Margin % for the quarter that ended in Mar. 2023 was -121.05%.

The historical rank and industry rank for Sangui Biotech International's Operating Margin % or its related term are showing as below:


SGBI's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.34
* Ranked among companies with meaningful Operating Margin % only.

Sangui Biotech International's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Sangui Biotech International's Operating Income for the three months ended in Mar. 2023 was $-0.02 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.11 Mil.


Sangui Biotech International Operating Margin % Historical Data

The historical data trend for Sangui Biotech International's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -270.13 -384.09 -624.14 -228.79 -201.45

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -155.56 -436.36 -39.02 -245.45 -121.05

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International Operating Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Operating Margin % falls into.



Sangui Biotech International Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sangui Biotech International's Operating Margin % for the fiscal year that ended in Jun. 2022 is calculated as

Operating Margin %=Operating Income (A: Jun. 2022 ) / Revenue (A: Jun. 2022 )
=-0.139 / 0.069
=-201.45 %

Sangui Biotech International's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=-0.023 / 0.019
=-121.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sangui Biotech International  (OTCPK:SGBI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sangui Biotech International Operating Margin % Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (Sangui Biotech International) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines